Medicare Enrolled
Dr. Abinav Baweja, MD
Medical Oncology · Pleasanton, CA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Baweja from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Baweja?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Baweja
Dr. Abinav Baweja is a medical oncology specialist in Pleasanton, CA, with 10 years of NPI registration. Based on federal Medicare data, Dr. Baweja performed 28,670 Medicare services across 2,180 unique beneficiaries.
Between the years covered by Open Payments, Dr. Baweja received a total of $2,495 from 38 pharmaceutical and/or device companies across 107 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Baweja is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 10 years in practice
▲ Top 13% volume in CA
$2,495 industry payments
Medicare Practice Summary
Medicare Utilization ↗28,670
Medicare services
Top 13% in CA for medical oncology
2,180
Unique beneficiaries
$19
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~2,867 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Anti-nausea injection (fosaprepitant) An injection of fosaprepitant, a medication used to prevent nausea and vomiting. |
10,200 | $0 | $6 |
| Denosumab injection (Prolia/Xgeva) | 4,020 | $18 | $54 |
| Epoetin alfa injection (Procrit) for anemia An injection of epoetin alfa containing 1000 units for use in patients not on end-stage renal disease (ESRD) dialysis. |
3,100 | $6 | $51 |
| Daratumumab injection (Darzalex) An injection containing daratumumab and hyaluronidase-fihj administered under the skin. |
2,340 | $38 | $159 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
1,581 | $0 | $1 |
| Anti-nausea injection (Aloxi/palonosetron) | 1,090 | $1 | $99 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
714 | $155 | $406 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
642 | $8 | $15 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
587 | $8 | $44 |
| Comprehensive metabolic blood panel A blood test that measures a group of chemicals, including glucose, electrolytes, and kidney and liver function markers. |
423 | $10 | $58 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
418 | $115 | $305 |
| Pegfilgrastim injection, 0.5 mg An injection of pegfilgrastim, a medication that stimulates the production of white blood cells. This specific code applies to the brand-name drug and excludes biosimilar versions. |
360 | $77 | $1,074 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
284 | $138 | $514 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
258 | $16 | $79 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
250 | $30 | $113 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
230 | $70 | $222 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
221 | $13 | $75 |
| Normal saline infusion, 250 cc Administration of 250 cubic centimeters of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater fluid. |
162 | $1 | $15 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
150 | $1 | $4 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
141 | $67 | $244 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
136 | $20 | $80 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
129 | $29 | $111 |
| New patient office visit, complex (60-74 min) | 108 | $176 | $569 |
| Normal saline infusion, 1000 cc Administration of 1000 cc of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater solution. |
108 | $2 | $9 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 108 | $134 | $2,106 |
| Lactate dehydrogenase (LDH) level test A blood test that measures the amount of lactate dehydrogenase, an enzyme found in many body tissues. It helps assess tissue damage or disease. |
107 | $6 | $27 |
| Non-hormonal chemotherapy injection This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue. |
86 | $77 | $207 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
85 | $154 | $585 |
| Uric acid level test A blood test that measures the level of uric acid in your body. Uric acid is a waste product formed when the body breaks down purines. |
76 | $4 | $20 |
| Ferritin level test (iron stores) A blood test that measures the level of ferritin, a protein that stores iron in the body. |
71 | $13 | $65 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
70 | $67 | $251 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
62 | $105 | $347 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
59 | $13 | $64 |
| Irrigation of implanted venous access device This procedure involves flushing an implanted venous access device to clear blockages or maintain patency. It ensures the device remains functional for delivering medications or fluids. |
55 | $25 | $90 |
| Subcutaneous or intramuscular chemotherapy injection This procedure involves administering anti-cancer hormonal medication through an injection into the tissue under the skin or into a muscle. |
51 | $34 | $141 |
| Venipuncture for blood collection A procedure to draw blood from a vein for medical testing or analysis. |
47 | $100 | $279 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
47 | $76 | $210 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
28 | $137 | $461 |
| Hospital follow-up visit, low complexity Follow-up hospital visit for an established patient with straightforward or low-level medical decision making. The visit requires at least 25 minutes of time spent on the day of service. |
27 | $43 | $145 |
| Prolonged office E/M service, first 15 minutes This code is used for additional time spent by a physician beyond the maximum required time of a primary office or outpatient evaluation and management service. It is billed in 15-minute increments based on total time spent on the date of the primary service. |
24 | $29 | $122 |
| Iron level test | 15 | $6 | $44 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
4.0% high complexity
82.3% medium
13.7% routine
Industry Payment Transparency
Open Payments through 2024 ↗$2,495
Total received (2020-2024)
Avg $624/year across 4 years
Bottom 42% in CA for medical oncology
38
Companies
107
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$2,413 (96.7%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$82 (3.3%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$25
2023
$1,858
2022
$516
2020
$97
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Novartis Pharmaceuticals Corporation
$25
Top 3 companies account for 100.0% of 2024 payments
All-time payments by company (2020-2024) ›
Seagen Inc.
$184
Janssen Biotech, Inc.
$179
Merck Sharp & Dohme LLC
$159
Celgene Corporation
$152
Daiichi Sankyo Inc.
$141
E.R. Squibb & Sons, L.L.C.
$127
Exelixis Inc.
$127
GENZYME CORPORATION
$122
PFIZER INC.
$116
Amgen Inc.
$113
Genentech USA, Inc.
$93
AstraZeneca Pharmaceuticals LP
$88
SANOFI-AVENTIS U.S. LLC
$82
Novartis Pharmaceuticals Corporation
$78
TAIHO ONCOLOGY, INC.
$60
Kite Pharma, Inc.
$57
Astellas Pharma US Inc
$50
Pharmacyclics LLC, An AbbVie Company
$48
EMD Serono, Inc.
$43
Taiho Oncology, Inc.
$39
Alnylam Pharmaceuticals Inc.
$38
Takeda Pharmaceuticals U.S.A., Inc.
$30
Sumitomo Pharma America, Inc.
$28
Octapharma USA, Inc.
$27
Gilead Sciences, Inc.
$27
Tactile Systems Technology Inc
$26
Bayer HealthCare Pharmaceuticals Inc.
$25
ImmunoGen, Inc.
$24
Mirati Therapeutics, Inc.
$24
ARRAY BIOPHARMA INC
$24
Apellis Pharmaceuticals, Inc.
$23
Foundation Medicine, Inc.
$23
Genmab U.S., Inc.
$22
Incyte Corporation
$22
EISAI INC.
$21
Bayer Healthcare Pharmaceuticals Inc.
$20
RECORDATI_RARE_DISEASES_INC.
$18
Eisai Inc.
$15
Top 3 companies account for 20.9% of all-time payments
Associated products mentioned in payments ›
Alecensa · BAVENCIO · BOSULIF · BRAFTOVI · CABOMETYX · CALQUENCE · Cabometyx · DARZALEX · ELITEK · ENHERTU · ERLEADA · Elahere · Epkinly · Flexitouch Plus · GIVLAARI · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · JAKAFI · JEVTANA · KEYTRUDA · KRAZATI · Kyprolis · LONSURF · LUMAKRAS · Lenvima · Lunsumio · NINLARO · Nplate · Nubeqa · OPDIVO · OPDUALAG · ORGOVYX · PADCEV · PANZYGA · Padcev · Perjeta · Pomalyst · REBLOZYL · RYBREVANT · SARCLISA · SCEMBLIX · SYLVANT · TEPMETKO · TUKYSA · Trodelvy · VPRIV · XTANDI · Yescarta
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (97%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Medical oncologists within 10 mi
8
Per 100K population
0.5
County median income
$126,240
Nearest hospital
STANFORD HEALTH CARE TRI-VALLEY
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Baweja is a mixed practice specialist, with above-average Medicare volume (top 13% in CA), with low-engagement industry engagement.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Baweja experienced with anti-nausea injection (fosaprepitant)?
Based on Medicare claims data, Dr. Baweja performed 10,200 anti-nausea injection (fosaprepitant) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Baweja receive payments from pharmaceutical companies?
Yes. Dr. Baweja received a total of $2,495 from 38 companies across 107 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Baweja's costs compare to other medical oncologists in Pleasanton?
Dr. Baweja's average Medicare payment per service is $19. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Baweja) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Medical Oncologists in Pleasanton
Browse medical oncologists in Pleasanton ranked by procedure volume and transparency data.
Highest volume
Top Medical Oncologists in CA
Medical oncologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Medical Oncologists in CA
Which CA medical oncologists receive the most from drug and device companies.
By company
Seagen Inc. Payments to Doctors
See all physicians who received payments from Seagen Inc.
By company
Janssen Biotech, Inc. Payments to Doctors
See all physicians who received payments from Janssen Biotech, Inc.
By company
Merck Sharp & Dohme LLC Payments to Doctors
See all physicians who received payments from Merck Sharp & Dohme LLC.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology